Dyne Therapeutics (NASDAQ:DYN) Given "Buy" Rating at Chardan Capital

Dyne Therapeutics (NASDAQ:DYN - Get Free Report)'s stock had its "buy" rating reissued by Chardan Capital in a report released on Friday,Benzinga reports. They presently have a $50.00 price target on the stock. Chardan Capital's price target points to a potential upside of 320.52% from the company's previous close.

A number of other research firms have also commented on DYN. Royal Bank of Canada restated an "outperform" rating and set a $45.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. HC Wainwright decreased their price target on Dyne Therapeutics from $55.00 to $46.00 and set a "buy" rating on the stock in a research report on Friday. Piper Sandler cut their price objective on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a research report on Friday. Robert W. Baird started coverage on shares of Dyne Therapeutics in a report on Friday, December 13th. They issued an "outperform" rating and a $46.00 target price on the stock. Finally, Raymond James raised shares of Dyne Therapeutics to a "strong-buy" rating in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $48.64.

Remove Ads

Dyne Therapeutics Stock Down 3.5 %

Shares of Dyne Therapeutics stock traded down $0.43 during trading on Friday, reaching $11.89. The company's stock had a trading volume of 3,031,714 shares, compared to its average volume of 2,283,139. Dyne Therapeutics has a 52 week low of $11.62 and a 52 week high of $47.45. The firm has a market cap of $1.21 billion, a PE ratio of -3.34 and a beta of 1.11. The business's 50-day moving average price is $16.75 and its 200-day moving average price is $27.26.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.04. Equities analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Insider Activity at Dyne Therapeutics

In other news, SVP Richard William Scalzo sold 1,455 shares of the business's stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $40,914.60. Following the sale, the senior vice president now directly owns 127,078 shares in the company, valued at approximately $3,573,433.36. The trade was a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Oxana Beskrovnaya sold 2,334 shares of the company's stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the transaction, the insider now directly owns 201,685 shares of the company's stock, valued at $5,671,382.20. This represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,387 shares of company stock valued at $142,789 in the last quarter. Insiders own 20.77% of the company's stock.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP acquired a new position in shares of Dyne Therapeutics during the third quarter worth $34,000. Point72 DIFC Ltd bought a new position in Dyne Therapeutics during the 3rd quarter worth $36,000. US Bancorp DE lifted its holdings in Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company's stock worth $49,000 after buying an additional 1,212 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Dyne Therapeutics in the 4th quarter valued at about $50,000. Finally, KBC Group NV increased its stake in shares of Dyne Therapeutics by 45.3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after buying an additional 978 shares during the period. 96.68% of the stock is owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.